Replimune Group (NASDAQ:REPL) Stock Price Down 3.5% – Here’s Why

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded down 3.5% during trading on Friday . The company traded as low as $13.14 and last traded at $13.27. 92,520 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 869,392 shares. The stock had previously closed at $13.75.

Analyst Ratings Changes

REPL has been the topic of a number of research reports. HC Wainwright increased their price target on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Financial Group increased their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $19.14.

Replimune Group Trading Down 1.2 %

The business’s 50 day moving average is $12.28 and its two-hundred day moving average is $11.35. The firm has a market capitalization of $929.79 million, a P/E ratio of -4.46 and a beta of 1.28. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Analysts expect that Replimune Group, Inc. will post -2.88 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its position in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Braidwell LP boosted its stake in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. State Street Corp raised its stake in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the period. Baker BROS. Advisors LP lifted its holdings in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its position in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after buying an additional 238,747 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.